Who are we ?

The public interest group Cancéropôle Île-de-France includes 7 member institutions and 14 partners, and brings together the entire cancer research community in the Paris region. To carry out its missions, it includes decision-making, scientific strategy and scientific evaluation bodies.

With funding from the Institut National du Cancer and its member institutions, its scientific strategy is based on thematic working groups, and aims to meet the specific needs of the Paris Region by integrating multidisciplinary and inter-institutional approaches.



The first measure in the contract drawn up between the French government and the Institut national du cancer (INCa) to steer the ten-year cancer strategy aims to continue the efforts undertaken to structure research in France. In this context, and following a positive evaluation of the Cancéropôles accredited over the 2017-2022 period, INCa has decided to relabel and fund the 7 French Cancéropôles for the 2023-2027 period. A budget of 1.125 million euros per year has been granted to Cancéropôle IDF for the duration of this label, to enable it to fulfill its missions.

INCa’s support has enabled the Cancéropôle to boost cancer research and innovation in the Paris Region since 2004. This funding, totalling 30.85 million euros between 2004 and 2022, has enabled the emergence of innovative research themes and new therapies. This support from INCa has helped make the Paris Region a key player in the fight against cancer.


Cancéropôle Île-de-France members contribute to its annual funding. These funds are allowing the General Secretariat to help implement its actions.

Paris Région

Cancers affect an increasing number of people every year. They are responsible for almost 30% of deaths in the Paris Region. The Cancéropôle Île-de-France brings together a network of excellence in cancer research laboratories and care facilities. The Regional Council funded the Cancéropôle IDF via its DIM (Domaines d’Intérêt Majeur) program between 2004 and 2016. The grants awarded by the Conseil régional d’Île-de-France have made it possible to allocate doctoral and post-doctoral grants to strengthen cancer research in the Paris region. This support has also been fundamental to the financing of equipment, making cutting-edge technologies available to all researchers in the region, enabling innovative research.